Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Alcon Research118 enrolled

Overview

The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

118

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

AL-12182 0.003% Ophthalmic SolutionDRUG

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

AL-12182 Ophthalmic Solution VehicleOTHER

Placebo

Latanoprost 0.005% Ophthalmic SolutionDRUG

Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older. * Diagnosis of open-angle glaucoma or ocular hypertension. * LogMAR visual acuity not worse than 0.6. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Clinically relevant ophthalmic or systemic conditions. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.